Cargando…

Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

Mobocertinib (TAK‐788) is a tyrosine kinase inhibitor under investigation for treatment of non–small cell lung cancer with activating EGFR exon 20 insertions. This study examined the safety; tolerability; pharmacokinetics (PK), including food effects; and bioavailability of mobocertinib in healthy v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Steven, Jin, Shu, Griffin, Celina, Feng, Zhongling, Lin, Jianchang, Baratta, Mike, Brake, Rachael, Venkatakrishnan, Karthik, Gupta, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453943/ https://www.ncbi.nlm.nih.gov/pubmed/34118178 http://dx.doi.org/10.1002/cpdd.951

Ejemplares similares

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers
por: Zhang, Steven, et al.
Publicado: (2021)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
por: Garcia Campelo, Maria Rosario, et al.
Publicado: (2022)

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2018)

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study
por: Gupta, Neeraj, et al.
Publicado: (2022)

Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers
por: Parikh, Neha, et al.
Publicado: (2016)

788 Upper Extremity and Lower Extremity Net Devices for Use after Application of Cultured Epidermal Autograft
por: Hayes, Callie J, et al.
Publicado: (2022)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
por: Arnold, Abram, et al.
Publicado: (2023)

Posters P788 - P999
Publicado: (2005)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2022)

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
por: Han, Han, et al.
Publicado: (2021)

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
por: Zhou, Caicun, et al.
Publicado: (2021)

Single Dose Comparative Bioavailability Study of Lisdexamfetamine Dimesylate as Oral Solution Versus Reference Hard Capsules in Healthy Volunteers
por: Rizea-Savu, Simona, et al.
Publicado: (2022)

The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations
por: Hernandez, Luis, et al.
Publicado: (2023)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development
por: Hanley, Michael J., et al.
Publicado: (2021)

A report on the clinical-pathological correlations of 788 gingival lesion
por: Gambino, Alessio, et al.
Publicado: (2017)

Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers*
por: Nahum, Méndez-Sánchez, et al.
Publicado: (2019)

Soft-capsule formulation of a re-esterified triglyceride omega-3 employing self-emulsifying technology and bioavailability evaluation in healthy volunteers
por: Sin, Gi Hyeong, et al.
Publicado: (2023)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
por: Gupta, Neeraj, et al.
Publicado: (2016)

Growth of Ceria Nano-Islands on a Stepped Au(788) Surface
por: Ma, Teng, et al.
Publicado: (2015)

788 INCREASE IN ALCOHOLIC HEPATITIS CASES DURING COVID PANDEMIC IN THE US
por: Nair, Geethu G., et al.
Publicado: (2021)

Correction to Lancet Child Adolesc Health 2022; 6: 788–98
Publicado: (2023)

Correction to Lancet Child Adolesc Health 2022; 6: 788–98
Publicado: (2022)

Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree(TM)) in Healthy Adult Subjects
por: Wang, Zhao, et al.
Publicado: (2021)

Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers
por: Inoue, Yushi, et al.
Publicado: (2012)

Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers
por: BRICIU, CORINA, et al.
Publicado: (2015)

Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2014)

Correction to: Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers*
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2019)

Correction to: Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers*
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2021)

run 1193 - p = 11.788 GeV/c - 8.5.1981, Verification and adjustment of the compensation for EM608/1 at p = 11.788 GeV/c
por: Swoboda, Detlef
Publicado: (1981)

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
por: LoRusso, Patricia, et al.
Publicado: (2013)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
por: Kamel, Josette, et al.
Publicado: (2021)

Bioavailability of a Lipidic Formulation of Curcumin in Healthy Human Volunteers
por: Pawar, Yogesh B., et al.
Publicado: (2012)

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
por: Imran, Mohd, et al.
Publicado: (2021)

2229. Relative Bioavailability of a Single Oral Dose of SUBA-Itraconazole 65 mg Capsule Compared with Conventional Itraconazole 100 mg Capsule Administered Under Fasted and Fed Conditions in Healthy Adult Volunteers
por: Mudge, Stuart, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_eeoqge5tjose0f8e1jc5gcbp7t